State of Alaska Department of Revenue Sells 59,405 Shares of Bristol Myers Squibb Company $BMY

State of Alaska Department of Revenue decreased its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 18.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 258,405 shares of the biopharmaceutical company’s stock after selling 59,405 shares during the quarter. State of Alaska Department of Revenue’s holdings in Bristol Myers Squibb were worth $13,938,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in BMY. Man Group plc lifted its position in Bristol Myers Squibb by 280.4% in the 2nd quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company’s stock valued at $345,594,000 after acquiring an additional 5,503,391 shares in the last quarter. Two Sigma Investments LP lifted its position in shares of Bristol Myers Squibb by 530.6% during the 3rd quarter. Two Sigma Investments LP now owns 5,453,357 shares of the biopharmaceutical company’s stock worth $245,946,000 after buying an additional 4,588,601 shares in the last quarter. Van ECK Associates Corp lifted its position in shares of Bristol Myers Squibb by 67.8% during the 3rd quarter. Van ECK Associates Corp now owns 9,859,915 shares of the biopharmaceutical company’s stock worth $444,682,000 after buying an additional 3,982,439 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its position in shares of Bristol Myers Squibb by 31.1% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 14,833,977 shares of the biopharmaceutical company’s stock worth $669,012,000 after buying an additional 3,522,696 shares in the last quarter. Finally, AQR Capital Management LLC lifted its position in shares of Bristol Myers Squibb by 56.0% during the 3rd quarter. AQR Capital Management LLC now owns 9,463,981 shares of the biopharmaceutical company’s stock worth $426,352,000 after buying an additional 3,396,041 shares in the last quarter. Institutional investors own 76.41% of the company’s stock.

Wall Street Analyst Weigh In

BMY has been the topic of several recent analyst reports. Guggenheim reissued a “buy” rating and set a $72.00 target price on shares of Bristol Myers Squibb in a research report on Wednesday, April 8th. Royal Bank Of Canada started coverage on shares of Bristol Myers Squibb in a research report on Tuesday, February 24th. They set a “sector perform” rating and a $60.00 target price on the stock. Piper Sandler reaffirmed an “overweight” rating and issued a $75.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, February 23rd. Leerink Partners lifted their price target on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an “outperform” rating in a report on Tuesday, January 13th. Finally, HSBC lifted their price target on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a report on Tuesday, March 17th. Nine investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $61.71.

Insider Activity at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 30,000 shares of the company’s stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total value of $1,850,100.00. Following the transaction, the executive vice president owned 159,248 shares of the company’s stock, valued at approximately $9,820,824.16. This represents a 15.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.09% of the stock is owned by insiders.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Cobenfy showing commercial momentum — grew to roughly $155M in 2025 and is outpacing peers, supporting upside potential from new indications. Does Cobenfy Have the Potential to Become a Top Drug for BMY?
• Positive Sentiment: New R&D collaboration with Oxford BioTherapeutics to discover next‑generation T‑cell engagers for solid tumors — expands BMS’s oncology pipeline and validates external discovery partnerships. Oxford BioTherapeutics Enters Strategic Collaboration with Bristol Myers Squibb…
• Positive Sentiment: Analyst support: Guggenheim reiterated a Buy rating, which can lend short-term confidence to the stock. Guggenheim Reiterates Buy Rating for Bristol Myers Squibb (NYSE:BMY)
• Neutral Sentiment: Dividend resilience noted — BMY highlighted as a recession‑resistant dividend stock, supporting income‑investor interest. 2 Recession Resistant Dividend Stocks to Buy Now While They’re Still Cheap
• Neutral Sentiment: Cantor Fitzgerald adjusted its price recommendation history (raised prior levels) but flagged Q1 catalysts are weak—mixed messaging that tempers conviction. Cantor Fitzgerald Lifts Bristol Myers (BMY) Price Target but Flags Weak Q1 Catalyst
• Neutral Sentiment: Macro note: BofA says many biopharma names are largely exempt from proposed pharma tariffs — a mild tailwind for the sector. Biopharma Stocks Largely Exempt From Pharma Tariffs, BofA Says
• Negative Sentiment: Near‑term revenue/earnings caution: a Zacks piece notes BMY’s YTD gains but warns generic erosion and the company’s 2026 sales outlook are reasons for investor caution. BMY Gains 10% Year to Date: Should You Buy, Sell or Hold the Stock?
• Negative Sentiment: Earnings risk: previews and analyst commentary expect a sizable Q1 earnings decline, which increases short‑term downside risk around the upcoming release. Bristol-Myers Squibb Earnings Preview: What to Expect
• Negative Sentiment: Some sell‑side adjustments show modestly lower price targets (Bank of America trimmed a target from $68 to $67; other outlets note PT shifts), signaling cautious near‑term sentiment. Benzinga

Bristol Myers Squibb Trading Down 0.0%

NYSE:BMY opened at $58.61 on Monday. The company has a current ratio of 1.26, a quick ratio of 1.14 and a debt-to-equity ratio of 2.32. The stock has a market capitalization of $119.66 billion, a PE ratio of 16.99, a price-to-earnings-growth ratio of 0.17 and a beta of 0.27. The firm’s 50 day moving average is $59.78 and its 200 day moving average is $53.24. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The company had revenue of $12.50 billion during the quarter, compared to the consensus estimate of $12.24 billion. During the same period last year, the firm posted $1.67 EPS. The company’s revenue for the quarter was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Sell-side analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.3%. The ex-dividend date of this dividend is Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 73.04%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.